Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid epidemic

Cigna Ends Preauthorization Requirement to Treat Opioid Addiction

Reuters Staff  |  October 22, 2016

(Reuters)—Health insurer Cigna Corp. has discontinued its policy of requiring doctors to seek authorization before treating opioid addicts, as part of a fight against an epidemic of opioid abuse, New York Attorney General Eric Schneiderman said on Friday. The policy change will apply nationally, says Schneiderman, who has been pushing for easier access to treatments…

Filed under:Legal Updates Tagged with:Cigna Corp.DrugsHealth InsuranceHealthcareOpioid abuseOpioids

U.S. Justice Department to Push Prosecutors on Opioids

Reuters Staff  |  September 18, 2016

WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…

Filed under:AnalgesicsDrug Updates Tagged with:Department of JusticeOpioidsOverdosePain

U.S. Republicans Reject Democratic Funding Proposals for Opioids

Reuters Staff  |  July 7, 2016

WASHINGTON (Reuters) – Republican lawmakers in U.S. Congress on Wednesday rejected two Democratic amendments to provide nearly $1 billion in funding for bipartisan legislation intended to combat America’s opioid epidemic, aides said. The rejection, which came during a meeting of U.S. House of Representatives and Senate negotiators on the measure, could undermine Democratic support for…

Filed under:Legislation & AdvocacyProfessional Topics

Monitoring Doctors Cuts Opioid Prescriptions

Ronnie Cohen  |  June 11, 2016

(Reuters Health)—Doctors in states that track painkiller prescriptions were nearly one-third less likely to offer patients dangerously addicting opioids, a new study found. The launch of drug-monitoring programs in 24 states led to an immediate 30 percent drop in prescriptions for Schedule II opioids, the most addictive, in patients with pain complaints, the study showed….

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyDrugsOpioidsphysicianprescription

FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

Natalie Grover & Toni Clarke  |  June 8, 2016

(Reuters)—A U.S. Food and Drug Administration (FDA) advisory panel recommended approving Teva Pharmaceuticals Industries Ltd’s long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties. The drug is designed for use every 12 hours for the management of pain severe enough to require around-the-clock treatment in patients who have…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painFDAFood and Drug AdministrationOpioidsTeva Pharmaceuticals

FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers

Reuters Staff  |  March 23, 2016

(Reuters)—The U.S. Food and Drug Administration announced on Tuesday new required class-wide safety labeling changes for immediate-release opioid pain medications. Among the changes, the FDA now requires these pain medications to carry a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. The FDA also requires several additional safety labeling…

Filed under:AnalgesicsDrug Updates Tagged with:FDAFood and Drug AdministrationGuidelinesOpioidsOverdose

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Centers for Disease Control and PreventionChronic painGuidelinesOpioids

10 Tips for Opioid Prescribing

Dennis J. Boyle, MD  |  December 1, 2014

How to manage the risks when prescribing medications for patients in chronic pain

Filed under:AnalgesicsAxial SpondyloarthritisConditionsDrug UpdatesPain Syndromes Tagged with:Ankylosing SpondylitisBoyleChronic paindruginfliximabopioidPainpatient careprednisoneprescriberheumatologist

Gout Research at a Glance

Lisa Stamp, MBChB, FRACP, PhD  |  November 28, 2022

PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2022ACR Convergence 2022 – Gout

whiteMocca / shutterstock.com

Virtual Reality Therapy Is Feasible for Rheumatology Patients

Ruth Jessen Hickman, MD  |  January 19, 2021

A recent pilot study explores the feasibility of virtual reality-based pain interventions for people with rheumatic con­ditions.1 Although the work is in its early stages, it may someday represent a new non-pharmacological tool for patients with chronic pain. VR for Treatment R. Swamy Venuturupalli, MD, FACR, is an associate clinical professor of medicine at the…

Filed under:ConditionsPain SyndromesResearch Rheum Tagged with:Chronic painmeditationPain ManagementTechnologyvirtual reality

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences